Clinical Relevance
The present study supports incorporation of prucalopride in colon-specific drug delivery systems to be used as a prokinetic for treating hypomotility disorders. Newer drug delivery systems targeting the colon use polysaccharide coatings that can be degraded only by the microorganisms existing in the colon which results in increased delivery success. With the advancement of nanotechnology, various forms of nanoparticle formulations for colon delivery have also been investigated (53) which could replace other types of colon-specific delivery systems in the future. This can be especially beneficial for high-risk populations such as the elderly and children.